Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | SRC positive |
| Therapy | KX2-391 |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SRC positive | triple-receptor negative breast cancer | sensitive | KX2-391 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tirbanibulin (KX2-391) inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709). | 22784709 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22784709) | Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. | Full reference... |